These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15897914)

  • 1. Metastatic prostate cancer presenting as an asymptomatic neck mass.
    Carleton J; van der Riet P; Dahm P
    Prostate Cancer Prostatic Dis; 2005; 8(3):293-5; discussion 295. PubMed ID: 15897914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical lymph node enlargement on the right side as the initial manifestation of metastatic prostate cancer.
    Ozgür A; Ilker Y; Türkeri LN
    Arch Esp Urol; 2003 Sep; 56(7):859-61. PubMed ID: 14595895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostatic carcinoma presenting with painless parotid mass.
    Kirkali Z; Koyuncuoğlu M; Pabuçcuoğlu U; Güneri A; Mungan U
    Urology; 1995 Sep; 46(3):406-7. PubMed ID: 7544935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
    Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
    Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate adenocarcinoma manifesting as generalized lymphadenopathy.
    Moura FM; Garcia LT; Castro LP; Ferrari TC
    Urol Oncol; 2006; 24(3):216-9. PubMed ID: 16678051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostatic carcinoma presenting with neck metastasis.
    McMenamin PG; Anderson JD; Baker JJ
    J Otolaryngol; 1989 Apr; 18(3):119-24. PubMed ID: 2716087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression.
    Heresi GA; Wang J; Taichman R; Chirinos JA; Regalado JJ; Lichtstein DM; Rosenblatt JD
    Urol Oncol; 2005; 23(4):261-7. PubMed ID: 16018941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer metastasis to supraclavicular lymph node.
    Hobdy EM; Shafi NQ; Kummar S
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):223-4; discussion 224. PubMed ID: 16163185
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment options in lymph node-positive prostate cancer.
    Swanson GP; Thompson IM; Basler J
    Cancer; 2006 Jun; 106(12):2531-9. PubMed ID: 16700035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K; Tomita Y
    Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck.
    Moore BA; Weber RS; Prieto V; El-Naggar A; Holsinger FC; Zhou X; Lee JJ; Lippman S; Clayman GL
    Laryngoscope; 2005 Sep; 115(9):1561-7. PubMed ID: 16148695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome.
    Swanson GP; Thompson IM; Basler J
    Cancer; 2006 Aug; 107(3):439-50. PubMed ID: 16795064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case study: management of advanced prostate cancer with soft tissue metastases.
    Kirby R
    Prostate Cancer Prostatic Dis; 2005; 8(3):290-2. PubMed ID: 15940287
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer metastatic to the stomach.
    Christoph F; Grünbaum M; Wolkers F; Müller M; Miller K
    Urology; 2004 Apr; 63(4):778-9. PubMed ID: 15072903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.